文章：

在化学免疫治疗时代，诊断为慢性淋巴细胞白血病的患者生存率提高：一项基于丹麦人群的10455例患者研究

Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients

原文发布日期：2016-11-11

DOI: 10.1038/bcj.2016.105

类型: Original Article

开放获取: 是

英文摘要：

The treatment of chronic lymphocytic leukemia (CLL) is in rapid transition, and during recent decades both combination chemotherapy and immunotherapy have been introduced. To evaluate the effects of this development, we identified all CLL patients registered in the nation-wide Danish Cancer Register between 1978 and 2013. We identified 10 455 CLL patients and 508 995 CLL-free control persons from the general population. Compared with the latter, the relative mortality rate between CLL patients and their controls decreased from 3.4 (95% CI 3.2–3.6) to 1.9 (95% CI 1.7–2.1) for patients diagnosed in 1978–1984 and 2006–2013, respectively. The improved survival corresponded to a decreasing risk of death from malignant hematological diseases, whereas the risk of death from infections was stable during the study period. These population-based data substantiate the improved survival for patients treated with chemo-immunotherapy demonstrated in clinical studies.

摘要翻译： 

慢性淋巴细胞白血病（CLL）的治疗正处于快速转型期，近几十年来联合化疗与免疫治疗相继问世。为评估这一进展的疗效，我们调取了1978至2013年间丹麦全国癌症登记库所有CLL患者数据，共纳入10,455例CLL患者及508,995名来自普通人群的非CLL对照者。数据显示，与对照组相比，CLL患者的相对死亡率从1978-1984年诊断队列的3.4（95%置信区间3.2-3.6）显著下降至2006-2013年诊断队列的1.9（95%置信区间1.7-2.1）。生存期的改善主要归因于血液系统恶性肿瘤相关死亡风险降低，而感染相关死亡风险在整个研究期间保持稳定。这项基于人群的研究证实了临床研究中化疗-免疫治疗方案带来的生存获益。

原文链接：

Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients